Concepedia

Suzanne Borgel

SB

Statistics

Publications

19

Citations

1.3K

H-Index

16

Active since

1997

Affiliations

National Cancer Institute(Current)

Frederick National Laboratory for Cancer Research

Science Applications International Corporation (United States)

Center for Cancer Research

Leidos (United States)

Suzanne Borgel is an author at National Cancer Institute specializing in medicine, oncology, and molecular oncology.

Publications per year

1997–2021

19

Publications

19

Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts

Annamaria Rapisarda, J. Zalek, Melinda G. Hollingshead et al. · Cancer Research · 2004 · 187 citations

Medicine, Oncology, Pharmacology +16

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

Annamaria Rapisarda, Melinda G. Hollingshead, Badarch Uranchimeg et al. · Molecular Cancer Therapeutics · 2009 · 172 citations · Full text

Medicine, Oncology, Pharmacology +15

Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC

Luke H. Stockwin, Sherry X. Yu, Suzanne Borgel et al. · International Journal of Cancer · 2010 · 156 citations

Medicine, Oncology, Pharmacology +17

In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative

Melinda G. Hollingshead, Michael C. Alley, Angelika M. Burger et al. · Cancer Chemotherapy and Pharmacology · 2005 · 151 citations

Medicine, Medicinal Chemistry, Pharmacology +5

Clinical Evolution of Epithelial–Mesenchymal Transition in Human Carcinomas

Tony Navas, Robert J. Kinders, Scott M. Lawrence et al. · Cancer Research · 2019 · 97 citations · Full text

Medicine, Cell Biology, Oncology +17

1–5 of 19